Etiqueta: spinal cord injury

The U.S. National Institutes of Health have released a draft of guidelines for human embryonic stem cell research, limiting the use of federal funds to research on «spare» embryos that were originally created for reproductive purposes only.

New legislation in the U.S. allows for tax benefits in the banking of adult stem cells derived from umbilical cord blood.

The biotech company Stempeutics has received regulatory authorization to commence the first clinical trial ever to be conducted with human stem cells in India, for the use of adult stem cell therapy in the treatment of two different diseases.

In FDA-approved clinical trials conducted in the U.S. with autologous adult stem cell therapy, heart patients show swift and significant improvement.

Doctors, scientists, and now also institutional investors lack confidence in Geron’s highly publicized upcoming clinical trial with human embryonic stem cells.

A young boy who was treated with fetal stem cell therapy developed a life-threatening tumor which was directly traced to the fetal stem cells that he received.

The company Neuralstem has been awarded a patent for its proprietary technology to immortalize human neural stem cells.

The stem cell company Neuralstem has filed an application with the FDA to begin the first clinical trials ever to be conducted with adult stem cells in the treatment of amyotrophic lateral sclerosis.

Scientists at the Salk Institute have demonstrated with human stem cells that an antioxidant commonly found in plants can improve amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

The stem cell company Neuralstem, Inc., announces the licensing of patents for the delivery of targeted spinal cord therapeutics.